Anticancer therapies and CNS relapse: overcoming blood–brain and blood–cerebrospinal fluid barrier impermeability

References

• Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med.353(16), 1673–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med.355(26), 2733–2743 (2006).
   PubMed Web of Science ®Google Scholar
• Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer : a 30-year follow-up. J. Clin. Oncol.10(7), 1044–1048 (1992).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med.355(24), 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N. Engl. J. Med.346(2), 92–98 (2002).
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA290(16), 2149–2158 (2003).
   PubMed Web of Science ®Google Scholar
• Fosella FV, Lee JS, Shong WK. Management strategies for recurrent non-small cell lung cancer. Semin. Oncol.24(4), 455–462 (1997).
   Google Scholar
• Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol.21(12), 2237–2246 (2003). Erratum in: J. Clin. Oncol.22(23), 4811 (2004).
   Google Scholar
• Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).Lancet366(9496), 1527–1537 (2005).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al.; for the National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med.353(2), 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Camacho LH, Antonia S, Sosman J et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin Oncol.27(7), 1075–1081 (2009).
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized Phase 3 intergroup trial. Blood108(10), 3295–3301 (2006).
   PubMed Web of Science ®Google Scholar
• Schulz H, Bohlius J, Skoetz N et al. Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin’s lymphoma. Cochrane Database Syst. Rev.17(4), CD003805 (2007).
   Google Scholar
• Cameron D, Casey M, Press M et al. A Phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat.112(3), 533–543 (2008).
   PubMed Web of Science ®Google Scholar
• Park YH, Park MJ, Ji SH et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br. J. Cancer100(6), 894–900 (2009).
   PubMed Web of Science ®Google Scholar
• Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab based therapy for metastatic breast carcinoma. Cancer97, 2972–2977 (2003).
   PubMed Web of Science ®Google Scholar
• Altaha R, Crowell E, Hobbs G, Higa G, Abraham J. Risk of brain metastases in HER2/neu-positive breast cancer. J. Clin. Oncol.22, S47 (2004).
   Google Scholar
• Clayton AJ, Danson S, Jolly S et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br. J. Cancer91(4), 639–643 (2004).
   PubMed Web of Science ®Google Scholar
• Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast15(2), 219–225 (2006).
   PubMed Web of Science ®Google Scholar
• Yau T, Swanton C, Chua S et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol.45(2), 196–201 (2006).
   PubMed Web of Science ®Google Scholar
• Pestalozzi BC, Zahrieh D, Price KN et al.; International Breast Cancer Study Group (IBCSG). Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann. Oncol.17(6), 935–944 (2006).
   PubMed Web of Science ®Google Scholar
• Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer94(10), 2698–2705 (2002).
   PubMed Web of Science ®Google Scholar
• Omuro AM, Kris MG, Miller VA et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer103(11), 2344–2348 (2005).
   PubMed Web of Science ®Google Scholar
• Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J. Clin. Oncol.22(14), 2865–2872 (2004).
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Reni M, Chiesa G et al. Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis. Cancer95(3), 605–612 (2002).
   PubMed Web of Science ®Google Scholar
• Law A, Karp DD, Dipetrillo T, Daly BT. Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced nonsmall cell lung carcinoma. Cancer92(1), 160–164 (2001).
   PubMed Web of Science ®Google Scholar
• Andre F, Grunenwald D, Pujol JL et al. Patterns of relapse of N2 non small-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered? Cancer91(12), 2394–2400 (2001).
   Google Scholar
• Robnett TJ, Machtay M, Stevenson JP, Algazy KM, Hahn SM. Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J. Clin. Oncol.19(5), 1344–1349 (2001).
   PubMed Web of Science ®Google Scholar
• Shimazu Y, Notohara K, Ueda Y. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int. J. Hematol.89(5), 577–583 (2009).
   PubMed Web of Science ®Google Scholar
• Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am. J. Surg.135(6), 807–810 (1978).
   PubMed Web of Science ®Google Scholar
• Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood113(17), 3896–3902 (2009).
   PubMed Web of Science ®Google Scholar
• Gabos Z, Sinha R, Hanson J et al. Prognostic significance of human epidermal growth factor receptor for the development of brain metastases after newly diagnosed breast cancer. J. Clin. Oncol.24(36), 5658–5663 (2006).
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J. Clin. Oncol.27(31), 5278–5286 (2009).
   PubMed Web of Science ®Google Scholar
• Aragon-Ching JB, Zujewski JA. CNS metastasis: an old problem in a new guise. Clin. Cancer Res.13(6), 1644–1647 (2007).
   PubMed Web of Science ®Google Scholar
• Palmieri D, Chambers AF, Felding-Habermann B, Huang S, Steeg PS. The biology of metastasis to a sanctuary site. Clin. Cancer Res.13(6), 1656–1662 (2007).
   PubMed Web of Science ®Google Scholar
• Nayak L, Abrey LE, Iwamoto FM. Intracranial dural metastases. Cancer115(9), 1947–1953 (2009).
   PubMed Web of Science ®Google Scholar
• Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv. Neurol.19, 579–592 (1978).
   PubMedGoogle Scholar
• Chamberlain MC. Are EGFR antagonists associated with increased central nervous system metastases in non-small cell lung cancer? Nat. Clin. Pract. Oncol.3(1), 20–21 (2006).
   Google Scholar
• Lin NU, Diéras V, Paul D et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res.15(4), 1452–1459 (2009).
   PubMed Web of Science ®Google Scholar
• Laterra J, Goldstein GW. Ventricular organisation of cerebrospinal fluid: blood–brain barrier, brain edema, and hydrocephalus. In: Principles of Neural Science (Fourth Edition). Kandel ER, Schwartz JH, Jessell TM (Eds). McGraw Hill, NY, USA 1288–1301 (2000).
   Google Scholar
• Deeken J, Löscher W. The blood–brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res.13(6), 1663–1674 (2007).
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Combs D, Rosenberg J et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood101(2), 466–468 (2003).
   PubMed Web of Science ®Google Scholar
• Heideman RL, Cole DE, Balis F et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res.49(3), 736–741 (1989).
   PubMed Web of Science ®Google Scholar
• Kerr IG, Zimm S, Collins JM, O’Neill D, Poplack DG. Effect of intravenous dose and schedule on cerebrospinal fluid pharmacokinetics of 5-fluorouracil in the monkey. Cancer Res.44(11), 4929–4932 (1984).
   PubMed Web of Science ®Google Scholar
• Heideman RL, Balis FM, McCully C, Poplack DG. Preclinical pharmacology of arabinosyl-5-azacytidine in nonhuman primates. Cancer Res.48(15), 4294–4298 (1988).
   Google Scholar
• DeGregorio MW, King OY, Holleran WM et al. Ultrafiltrate and total platinum in plasma and cerebrospinal fluid in a patient with neuroblastoma. Cancer Treat. Rep.69(12), 1441–1442 (1985).
   PubMedGoogle Scholar
• Relling MV, Mahmoud HH, Pui CH et al. Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. J. Clin. Oncol.14(2), 399–404 (1996).
   PubMed Web of Science ®Google Scholar
• Thyss A, Milano G, Deville A, Manassero J, Renee N, Schneider M. Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies. Eur. J. Cancer Clin. Oncol.23(6), 843–847 (1987).
   PubMedGoogle Scholar
• Collins JM, Riccardi R, Trown P, O’Neill D, Poplack DG. Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon a A in monkeys: comparison of intravenous, intramuscular, and intraventricular delivery. Cancer Drug Deliv.2(4), 247–253 (1985).
   PubMedGoogle Scholar
• Harjunpää A, Wiklund T, Collan J et al. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk. Lymphoma42(4), 731–738 (2001).
   PubMed Web of Science ®Google Scholar
• Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J. Clin. Oncol.18(11), 2349–2351 (2000).
   PubMed Web of Science ®Google Scholar
• Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier. Anticancer Drugs18(1), 23–28 (2007).
   PubMed Web of Science ®Google Scholar
• Polli JW, Olson KL, Chism JP et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab. Dispos.37(2), 439–442 (2009).
   PubMed Web of Science ®Google Scholar
• Neville K, Parise RA, Thompson P et al. Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin. Cancer Res.10(7), 2525–2529 (2004).
   PubMed Web of Science ®Google Scholar
• Porkka K, Koskenvesa P, Lundán T et al. Dasatinib crosses the blood–brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood112(4), 1005–1012 (2008).
   PubMed Web of Science ®Google Scholar
• Polli JW, Humphreys JE, Harmon KA et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab. Dispos.36(4), 695–701 (2008).
   PubMed Web of Science ®Google Scholar
• de Vries NA, Beijnen JH, Boogerd W, van Tellingen O. blood–brain barrier and chemotherapeutic treatment of brain tumors. Expert Rev. Neurother.6(8), 1199–1209 (2006).
   PubMedGoogle Scholar
• Neuwelt E, Abbott NJ, Abrey L et al. Strategies to advance translational research into brain barriers. Lancet Neurol.7(1), 84–96 (2008).
   PubMed Web of Science ®Google Scholar
• Ewend MG, Brem S, Gilbert M et al. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin. Cancer Res.13(12), 3637–3641 (2007).
   PubMed Web of Science ®Google Scholar
• Ferguson SD, Foster K, Yamini B. Convection-enhanced delivery for treatment of brain tumors. Expert Rev. Anticancer Ther.7(12 Suppl.), S79–S85 (2007).
   PubMed Web of Science ®Google Scholar
• Hall WA. Convection-enhanced delivery: neurosurgical issues. Curr. Drug Targets10(2), 126–130 (2009).
   PubMed Web of Science ®Google Scholar
• Mamelak AN, Jacoby DB. Targeted delivery of anti-tumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin. Drug Deliv.4(2), 175–186 (2007).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Zalutsky MR, Bigner DD. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev. Anticancer Ther.7(5), 675–687 (2007).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Zalutsky MR, Akabani G et al. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol.10(2), 182–189 (2008).
   PubMed Web of Science ®Google Scholar
• Fortin D, Gendron C, Boudrias M, Garant MP. Enhanced chemotherapy delivery by intraarterial infusion and blood–brain barrier disruption in the treatment of cerebral metastasis. Cancer109(4), 751–760 (2007).
   PubMed Web of Science ®Google Scholar
• Marchi N, Angelov L, Masaryk T et al. Seizure-promoting effect of blood–brain barrier disruption. Epilepsia48(4), 732–742 (2007).
   PubMed Web of Science ®Google Scholar
• Fortin D, McAllister LD, Nesbit G et al. Unusual cervical spinal cord toxicity associated with intra-arterial carboplatin, intra-arterial or intravenous etoposide phosphate, and intravenous cyclophosphamide in conjunction with osmotic blood brain-barrier disruption in the vertebral artery. AJNR Am. J. Neuroradiol.20(10), 1794–1802 (1999).
   Google Scholar
• Blacklock JB, Wright DC, Dedrick RL et al. Drug streaming during intra-arterial chemotherapy. J. Neurosurg.64(2), 284–291 (1986).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Nolan C, Abrey LE. Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. J. Neurooncol.75(1), 71–83 (2005).
   PubMedGoogle Scholar
• Mehta MP, Rodrigus P, Terhaard CH et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J. Clin. Oncol.21(13), 2529–2536 (2003).
   PubMed Web of Science ®Google Scholar
• Laack NN, Brown PD. Cognitive sequelae of brain radiation in adults. Semin. Oncol.31(5), 702–714 (2004).
   PubMed Web of Science ®Google Scholar
• Stemmler J, Schmitt M, Willems A et al. Brain metastases in HER2-overexpressing metastatic breast cancer: comparative analysis of trastuzumab levels in serum and cerebrospinal fluid [abstract 1525]. J. Clin. Oncol.24, S64 (2006).
   Google Scholar
• Wang JJ, Freeman AI, Sinks LF. Treatment of acute lymphocytic leukemia by high-dose intravenous methotrexate. Cancer Res.36(4), 1441–1444 (1976).
   PubMed Web of Science ®Google Scholar
• Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N. Engl. J. Med.293(4), 161–166 (1975).
   PubMed Web of Science ®Google Scholar
• Skarin AT, Zuckerman KS, Pitman SW et al. High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood50(6), 1039–1047 (1977).
   PubMed Web of Science ®Google Scholar
• Frei E 3rd, Blum RH, Pitman SW et al. High dose methotrexate with leucovorin rescue. Rationale and spectrum of anti-tumor activity. Am. J. Med.68(3), 370–376 (1980).
   PubMed Web of Science ®Google Scholar
• Evans WE, Hutson PR, Stewart CF et al. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Clin. Pharmacol. Ther.33(3), 301–307 (1983).
   PubMed Web of Science ®Google Scholar
• Vassal G, Valteau D, Bonnay M, Patte C, Aubier F, Lemerle J. Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkin’s lymphoma. Pediatr. Hematol. Oncol.7(1), 71–77 (1990).
   PubMed Web of Science ®Google Scholar
• Glantz MJ, Cole BF, Recht L et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J. Clin. Oncol.16(4), 1561–1567 (1998).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Neoplastic meningitis. Neurologist12(4), 179–187 (2006).
   PubMed Web of Science ®Google Scholar
• Methotrexate injection USP, package insert. GeneraMedix Inc., NJ, USA.
   Google Scholar
• Cytarabine injection, package insert. Hospira Inc., IL, USA.
   Google Scholar
• Thiotepa injection, package insert. GensioSicor Inc., CA, USA.
   Google Scholar
• Green MR, Chamberlain MC. Renal dysfunction during and after high-dose methotrexate. Cancer Chemother. Pharmacol.63(4), 599–604 (2009).
   PubMed Web of Science ®Google Scholar
• Reid J, Stevens D, Rubin J, Ames MM. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4 carboximide following administration of temozolomide to patients with advanced cancer. Clin. Cancer Res.3(12 Pt 1), 2393–2398 (1997).
   PubMed Web of Science ®Google Scholar
• Antonadou D, Paraskevaidis M, Sarris G et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J. Clin. Oncol.20(17), 3644–3650 (2002).
   PubMed Web of Science ®Google Scholar
• Verger E, Gil M, Yaya R et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a Phase II randomized trial. Int. J. Radiat. Oncol. Biol. Phys.61(1), 185–191 (2005).
   PubMed Web of Science ®Google Scholar
• Neuhaus T, Ko Y, Muller RP et al. A Phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br. J. Cancer100(2), 291–297 (2009).
   PubMed Web of Science ®Google Scholar
• Conlin AK, D’Andrea G, Hudis CA et al. Phase II trial of patupilone in patients with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiation therapy (WBXRT). J. Clin. Oncol.26(15S), S62 (2008) (abstract 1086).
   Google Scholar
• Glück S, Castrellon A. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases. Am. J. Ther.16(6), 585–590 (2009).
   Google Scholar
• Glantz MJ, Van Horn A, Chamberlain MC. Route of intra-CSF chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer (2009) (In press).
   Google Scholar
• Chamberlain MC. Neoplastic meningitis. J. Clin. Oncol.23(15), 3605–3613 (2005).
   PubMed Web of Science ®Google Scholar
• Cole BF, Glantz MJ, Jaeckle KA, Chamberlain MC, Mackowiak JI. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer97(12), 3053–3060 (2003).
   PubMed Web of Science ®Google Scholar
• Glantz MJ, Jaeckle KA, Chamberlain MC et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res.5(11), 3394–3402 (1999).
   PubMed Web of Science ®Google Scholar
• Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J. Clin. Oncol.11(3), 561–569 (1993).
   PubMed Web of Science ®Google Scholar
• Waki F, Ando M, Takashima A et al. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J. Neurooncol.93(2), 205–212 (2009).
   PubMed Web of Science ®Google Scholar
• Glantz MJ, LaFollette S, Jaeckle KA et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J. Clin. Oncol.17(10), 3110–3116 (1999).
   PubMed Web of Science ®Google Scholar
• Jaeckle KA, Batchelor T, O’Day SJ et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J. Neurooncol.57(3), 231–239 (2002).
   PubMed Web of Science ®Google Scholar
• Garcia-Marco JA, Panizo C, Garcia ES et al. Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer115(9), 1892–1898 (2009).
   PubMed Web of Science ®Google Scholar
• Fischer PG, Kadan-Lottick NS, Korones DN. Intrathecal thiotepa: reappraisal of an established therapy. J. Pediatr. Hematol. Oncol.24(4), 274–278 (2002).
   Google Scholar
• Groves MD, Glantz MJ, Chamberlain MC et al. A multicenter Phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol.10(2), 208–215 (2008).
   Google Scholar
• Chamberlain MC. A Phase II trial of intra-cerebrospinal fluid a interferon in the treatment of neoplastic meningitis. Cancer94(10), 2675–2680 (2002).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Tsao-Wei DD, Groshen S. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer106(9), 2021–2027 (2006).
   Google Scholar
• Bernardi RJ, Bomgaars L, Fox E et al. Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother. Pharmacol.62(2), 355–361 (2008).
   Google Scholar
• Wong F, Groves M, Conrad C et al. A Phase I study using intralumbar injection of I-131 sodium iodide to treat leptomeningeal metastases (LM). Presented at: American Academy of Neurology 60th Annual Meeting. Chicago, IL, USA, 12–19 April 2008. (Abstract P03.138).
   Google Scholar
• Rebischung C, Hoffmann D, Stefani L et al. First human treatment of resistant neoplastic meningitis by intrathecal administration of MTX plus (125)IUdR. Int. J. Radiat. Biol.84(12), 1123–1129 (2008).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Johnston SK, Van Horn A, Glantz MJ. Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J. Neurooncol.91(3), 271–277 (2009).
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Fridlyand J, Abrey L et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J. Clin. Oncol.25(11), 1350–1356 (2007).
   PubMed Web of Science ®Google Scholar
• Jaime-Pérez JC, Rodríguez-Romo LN, González-Llano O, Chapa-Rodríguez A, Gómez-Almaguer D. Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy. Br. J. Haematol.144(5), 794–795 (2009).
   PubMed Web of Science ®Google Scholar
• Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann. Oncol.19(11), 1978–1980 (2008).
   PubMed Web of Science ®Google Scholar
• Ferrario C, Davidson A, Bouganim N, Aloyz R, Panasci LC. Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann. Oncol.20(4), 792–795 (2009).
   PubMed Web of Science ®Google Scholar
• Allison D, Glantz M. Intra-CSF trastuzumab in patients with neoplastic meningitis from breast cancer or primary brain tumors. Presented at: 61st Annual Meeting of the American Academy of Neurology. Seattle, WA, USA, 25 April–2 May 2009. (Poster P01.086).
   Google Scholar
• Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma: a 20-year follow-up analysis of SWOG 8516 – the Southwest Oncology Group. J. Clin. Oncol.27(1), 114–119 (2009).
   PubMed Web of Science ®Google Scholar
• Gaspar LE, Chansky K, Albain KS et al. From treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J. Clin. Oncol.23(13), 2955–2961 (2005).
   PubMed Web of Science ®Google Scholar
• Hegde U, Filie A, Little RF et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood105(2), 496–502 (2005).
   PubMed Web of Science ®Google Scholar
• Bromberg JE, Breems DA, Kraan J et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology68(20), 1674–1679 (2007).
   PubMed Web of Science ®Google Scholar
• Quijano S, López A, Manuel Sancho J et al; Spanish Group for the Study of CNS Disease in NHL. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin’s lymphoma: improved sensitivity of flow cytometry. J. Clin. Oncol.27(9), 1462–1469 (2009).
   PubMed Web of Science ®Google Scholar
• Van Horn A. Lymphomatous meningitis: early diagnosis and treatment. Clin. J. Oncol. Nurs.13(1), 90–94 (2009).
   Google Scholar
• Boogerd W, van den Bent MJ, Koehler PJ et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomized study. Eur. J. Cancer40(18), 2726–2733 (2004).
   PubMed Web of Science ®Google Scholar
• Rogers LR, Chamberlain M, Glantz M. Evidence-based review of intrathecal chemotherapy in outcome of patients with leptomeningeal metastasis. J. Clin. Oncol.24(18S), S65 Abstract 1529 (2006).
   Google Scholar
• Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl Acad. Sci. USA93(24), 14164–14169 (1996).
   PubMed Web of Science ®Google Scholar
• Boado RJ, Zhang Y, Zhang Y, Xia CF, Pardridge WM. Fusion antibody for Alzheimer’s disease with bidirectional transport across the blood–brain barrier and ab fibril disaggregation. Bioconjug. Chem.18(2), 447–455 (2007).
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Fraga CH, Hubbard KE et al. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. Cancer Res.66(23), 11305–11313 (2006).
   PubMed Web of Science ®Google Scholar
• Shen J, Carcaboso AM, Hubbard KE et al. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Res.69(14), 5885–5892 (2009).
   PubMed Web of Science ®Google Scholar